Please assess the completion status of the following clinical trial:

Trial Title: Pneumococcal Adult-dose Ranging Immunization Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Age 70 through 79 years (up to the day prior to the 80th birthday)~* Previously received exactly one dose of PPV23, and that dose was received on or after their 65th birthday and at least 5 years before the date of study enrollment~* Expected to reside in the area for at least 13 months~* Able to understand and give informed consent~* Able to perform study procedures~* Able to be contacted by telephone for follow-up on adverse events~Exclusion Criteria:~* Received \>=2 doses of PPV23 prior to study enrollment.~* Living non-independently in an institutional setting, such as a nursing home. Persons living independently in adult residence communities will be eligible.~* Use of any investigational vaccine within the past 30 days or planned use during the study period.~* Current or planned participation in a research study of an investigational drug. Participation in research studies that involve use of licensed drugs, for either approved or investigational indications, will be permitted with the approval of the site PI, as will participation in research studies that do not involve medications.~* Current use or previous chronic administration, defined as \>=14 days during the previous six months, of immunosuppressants or other immune-modifying drugs. (For oral or injected corticosteroids, the immune-modifying dose is defined as prednisone or its equivalent \>=10 mg/day). Topical steroids are allowed.~* Current use of high doses of inhaled steroids, defined as per Table 3.~* Use of cytotoxic therapy in the previous 5 years.~* Plans to receive cytotoxic therapy during the study period.~* Receipt of parenteral immunoglobulin or blood products within three months of study.~* Plans to receive parenteral immunoglobulin or blood products within the study period.~* Current ongoing use of warfarin or heparin or has a bleeding disorder, such as ITP.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection.~* Anatomic or known functional asplenia.~* History of a hematologic malignancy or a pre-malignant condition (i.e., leukemia, lymphoma, multiple myeloma, myelodysplasia).~* Active neoplastic disease, excluding local skin cancer or other malignancies (e.g. prostate cancer) that are stable in the absence of immunosuppressive/cytotoxic or radiation therapy.~* End-stage liver disease or hepatic failure (as diagnosed by a physician or evidenced by a history within the last 10 years of bleeding esophageal varices, ascites, or hepatic encephalopathy).~* Renal failure, as evidenced by current or expected dialysis or known creatinine of \>=2.5 ug/ml.~* Known hypersensitivity to PPV23 or to any component of PPV23 or PCV7, including aluminum phosphate or diphtheria protein.~* Presence of any other condition or impairment that in the opinion of the investigator is likely to compromise the participant's ability to complete the study procedures.

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- 0.1mL Pneumococcal Conjugate Vaccine (Type: EXPERIMENTAL): Participants in this group were randomized at enrollment to receive 0.1mL PCV7, Prevnar® at the enrollment visit and then 0.1mL Pneumococcal Polysaccharide Vaccine 12 months later.
- 0.5mL Pneumococcal Conjugate Vaccine (Type: EXPERIMENTAL): Participants in this group were randomized at enrollment to receive 0.5mL PCV7, Prevnar® at the enrollment visit and then 0.1mL Pneumococcal Polysaccharide Vaccine 12 months later.
- 1.0mL Pneumococcal Conjugate Vaccine (Type: EXPERIMENTAL): Participants in this group were randomized at enrollment to receive 1.0mL PCV7, Prevnar® at the enrollment visit and then 0.1mL Pneumococcal Polysaccharide Vaccine 12 months later.
- 2.0mL Pneumococcal Conjugate Vaccine (Type: EXPERIMENTAL): Participants in this group were randomized at enrollment to receive 2.0mL PCV7, Prevnar® at the enrollment visit and then 0.1mL Pneumococcal Polysaccharide Vaccine 12 months later.
- 0.5mL Pneumococcal Polysacc Vaccine (Type: EXPERIMENTAL): Participants in this group were randomized at enrollment to receive 0.5mL Pneumovax 23 at the enrollment visit and then 0.1mL Pneumococcal Polysaccharide Vaccine 12 months later.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete